|
|
|
|
BiomedReports: FDA Calendar Updates for Eisai (OTC:ESALY), King Pharma (NYSE:KG), Myriad Pharma (NASDAQ:MYRX)
(M2 PRESSWIRE via COMTEX) -- BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has new updates to it's database of FDA and...
|
|
|
Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Pa
Eisai Co., Ltd.(Headquarters: Tokyo, President & CEO: Haruo Naito, 'Eisai') and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical...
|
|
|
Acura And King Receive FDA Complete Response Letter Regarding Acurox(R)
Acura Pharmaceuticals, Inc.(Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug Application (NDA)...
|
|
|
POZEN Submits New Drug Application For VIMOVO' (PN 400)
POZEN Inc.(NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric coated (EC) naproxen and...
|
|
|
POZEN Submits New Drug Application For VIMOVO (PN 400)
POZEN Inc.(NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric coated (EC) naproxen and...
|
|
|
Photocure submits application for marketing approval for Hexvix in USA to the FDA
--Photocure announces today that a New Drug Application (NDA) has been submitted to the US Health Authorities (FDA) to obtain approval for Hexvix for use in the detection of papillary bladder cancer using fluorescence cystoscopy.The...
|
|
|
Photocure submits application for marketing approval for Hexvix, in USA to the FDA
Photocure announces today that a New Drug Application (NDA) has been submitted to the US Health Authorities (FDA) to obtain approval for Hexvix for use in the detection of papillary bladder cancer using fluorescence cystoscopy.The ...
|
|
|
Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
Companies mentioned in this article: King Pharmaceuticals, Inc.PALATINE, Ill. and BRISTOL, Tenn., July 2 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today...
|
|
|
FDA Calendar Updates: Repros, Discovery, Acorda, Human Genome Sciences
Below is a summary of updates to the , which includes a database of over 200 entries.I originally created this calendar to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With...
|
|
|
Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Pa
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , President & CEO: Haruo Naito 1. Sustained Release Tablets Eisai has completed a Phase III study of Aricept 23 mg sustained release (SR)...
|
|
|
Acura Pharma, King Pharma Receive FDA Complete Response Letter Regarding NDA For Acurox - Quick Facts
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Acura Pharmaceuticals, Inc.(ACUR: News ) and King Pharmaceuticals, Inc. (KG: News ) announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding...
|
|
|
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cuta
Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced...
|
|
|
PPD Confirms Takeda Receives FDA Complete Response For Alogliptin
PPD, Inc.(NASDAQ: PPDI) today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete...
|
|
|
ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
- Final manufacturing activities for ANX-530 NDA re-started SAN DIEGO, June 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.(NYSE Amex: ANX) today announced its plans for the remainder of 2009. Following the financing...
|
|
|
ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
- Final manufacturing activities for ANX-530 NDA re-started SAN DIEGO, June 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.(NYSE Amex: ANX) today announced its plans for the remainder of 2009. Following the financing...
|
|
|
AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
3652 live jobs on PharmiWeb.com now VIMOVO Proposed as trade name AstraZeneca today announced that its development partner, Pozen, Inc., has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for VIMOVO...
|
|
|
POZEN Submits New Drug Application For VIMOVO (PN 400)
POZEN Inc.(NASDAQ:POZN),today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric coated (EC) naproxen...
|
|
|
Javelin Pharmaceuticals Completes Observational Safety Study of Dyloject
(Close-Up Media via COMTEX) -- JAV | Quote | Chart | News | PowerRating -- Javelin Pharmaceuticals reported that it has completed its open-label multi-dose, multi-day, observational safety study of Dyloject in the United States and that the...
|
|
|
AstraZeneca, Pozen Submit New Drug Application For PN400
PN400, a fixed-dose combination of enteric coated naproxen and esomeprazole AstraZeneca has announced that its development partner, Pozen has submitted a New Drug Application (NDA) to the FDA, for VIMOVO (PN400) tablets.PN400 is...
|
|
|
AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
AstraZeneca announced that its development partner, Pozen, Inc., has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for VIMOVO (PN400) (enteric coated naproxen/esomeprazole magnesium) tablets, a...
|
|
|
Feraheme Expects FDA Decision On Feraheme' NDA Soon
but letter would be issued in next few days AMAG Pharmaceuticals has announced that it has not received an action letter from FDA for Feraheme (ferumoxytol) Injection, for the treatment of iron deficiency anemia in adult chronic kidney...
|
|
|
ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
ADVENTRX Pharmaceuticals, Inc.today announced its plans for the remainder of 2009. Following the financing that closed earlier this month, ADVENTRX has re-started the final manufacturing activities related to submitting an NDA for...
|
|
|
GE Healthcares Application for DaTSCAN Ioflupane I123 Injection Accepted by the FDA for Priority Review
- (NewsRx.com) -- GE Healthcare announced that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a radiopharmaceutical agent...
|
|
|
POZEN Submits New Drug Application For VIMOVO (PN 400)
- POZEN Inc.(NASDAQ:POZN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO (PN 400), the combination of enteric coated (EC)...
|
|
|
AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
-AstraZeneca today announced that its development partner, Pozen, Inc., has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for VIMOVO (PN400) (enteric coated naproxen /esomeprazole magnesium)...
|
